These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 9766341)

  • 1. Assessing the benefits of lipid-lowering therapy.
    Gotto AM
    Am J Cardiol; 1998 Sep; 82(6A):2M-4M. PubMed ID: 9766341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease.
    Hay JW; Yu WM; Ashraf T
    Pharmacoeconomics; 1999 Jan; 15(1):47-74. PubMed ID: 10345158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic implications of lipid-lowering trials: current considerations in selecting a statin.
    Farmer JA
    Am J Cardiol; 1998 Sep; 82(6A):26M-31M. PubMed ID: 9766345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-benefit analysis of lipid lowering therapy.
    Jönsson B; Johannesson M
    Eur Heart J; 1997 Jan; 18(1):165-6. PubMed ID: 9049529
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of lipid-lowering therapy on total and coronary mortality.
    Holme I
    Curr Opin Lipidol; 1995 Dec; 6(6):374-8. PubMed ID: 8750251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economics of lipid lowering in primary prevention: lessons from the West of Scotland Coronary Prevention Study.
    Shepherd J
    Am J Cardiol; 2001 Mar; 87(5A):19B-22B. PubMed ID: 11256845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacologic concepts for the rational selection and use of drugs for the management of dyslipidemia.
    Dujovne CA; Moriarty PM
    Clin Ther; 1996; 18(3):392-410; discussion 391. PubMed ID: 8829016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender-based mortality follow-up from the Program on the Surgical Control of the Hyperlipidemias (POSCH) and meta-analysis of lipid intervention trials. Women in POSCH and other lipid trials.
    Buchwald H; Campos CT; Boen JR; Nguyen P; Williams SE; Lau J; Chalmers TC
    Ann Surg; 1996 Oct; 224(4):486-98; discussion 498-500. PubMed ID: 8857853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials.
    Lancet; 1996 Nov; 348(9038):1339-42. PubMed ID: 8918276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simvastatin. A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease.
    Goa KL; Barradell LB; McTavish D
    Pharmacoeconomics; 1997 Jan; 11(1):89-110. PubMed ID: 10172918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of intensive lipid lowering on coronary atheroma and clinical outcome.
    Houslay ES; Sarma J; Uren NG
    Heart; 2007 Feb; 93(2):149-51. PubMed ID: 17035507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of 4S evidence on baseline lipid levels.
    Jacobson TA
    Lancet; 1995 Jul; 346(8968):181-2. PubMed ID: 7603245
    [No Abstract]   [Full Text] [Related]  

  • 13. Angiographic trials of lipid-lowering therapy: an update.
    Mancini GB
    Curr Opin Lipidol; 1995 Dec; 6(6):379-85. PubMed ID: 8750252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Justifying lipid-lowering therapy in persons >/=65 years of age.
    LaRosa JC
    Am J Cardiol; 2002 Dec; 90(12):1330-2. PubMed ID: 12480043
    [No Abstract]   [Full Text] [Related]  

  • 15. Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation.
    Ara R; Pandor A; Stevens J; Rees A; Rafia R
    Health Technol Assess; 2009 Jul; 13(34):1-74, 75-118. PubMed ID: 19604457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of 4S evidence on baseline lipid levels.
    Ravnskov U
    Lancet; 1995 Jul; 346(8968):181. PubMed ID: 7603244
    [No Abstract]   [Full Text] [Related]  

  • 17. Lipid-lowering drug use and cardiovascular events after myocardial infarction.
    Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM
    Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-benefit analysis of lipid lowering therapy.
    Davie AP; McMurray JJ
    Eur Heart J; 1996 Jul; 17(7):974-5. PubMed ID: 8809507
    [No Abstract]   [Full Text] [Related]  

  • 19. The Lipoprotein and Coronary Atherosclerosis Study (LCAS) in context: assessing the benefits of lipid-lowering therapy. Introduction.
    Gotto AM
    Am J Cardiol; 1998 Sep; 82(6A):1M. PubMed ID: 9766340
    [No Abstract]   [Full Text] [Related]  

  • 20. Coronary artery disease: the Scandinavian Simvastatin Survival Study experience.
    Pedersen TR
    Am J Cardiol; 1998 Nov; 82(10B):53T-56T. PubMed ID: 9860376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.